BioCryst Pharmaceuticals
BCRX
235 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 84 increasing their positions, 76 reducing their positions, and 26 closing their positions.
144% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $9.05M
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
11% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 76
1% more funds holding
Funds holding: 233 → 235 (+2)
4.85% less ownership
Funds ownership: 92.75% → 87.89% (-4.9%)
13% less capital invested
Capital invested by funds: $1.24B → $1.08B (-$166M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$25.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 4 |
BlackRock
New York
|
+$11.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$24.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.5M |
| 3 |
Millennium Management
New York
|
-$19.2M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$16.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Allspring Global Investments
Charlotte,
North Carolina
| – | -$17.5K | -2,478 | Closed |
|
|
IUHSA
252
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| – | -$2.67K | -377 | Closed |
|
|
BCPWM
253
Bradley & Co Private Wealth Management
Miami,
Florida
| – | -$2.62K | -370 | Closed |
|
|
PTC
254
Private Trust Company
Cleveland,
Ohio
| – | -$1.63K | -230 | Closed |
|
|
BIA
255
Bell Investment Advisors
Oakland,
California
| – | -$935 | -132 | Closed |
|
|
PPC
256
Park Place Capital
Homewood,
Alabama
| – | -$793 | -112 | Closed |
|
|
BAAM
257
Baker Avenue Asset Management
San Francisco,
California
| – | -$496 | -70 | Closed |
|
|
PA
258
Parallel Advisors
San Francisco,
California
| – | -$283 | -40 | Closed |
|
|
NA
259
NewEdge Advisors
New Orleans,
Louisiana
| – | -$212 | -30 | Closed |
|
|
IA
260
IFP Advisors
Tampa,
Florida
| – | -$177 | -25 | Closed |
|
|
C
261
Covestor
London,
United Kingdom
| – | +$17 | +3 | +19% |
|
BCRX Hedge Fund Activity: Q4 2023 in Review
235 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2023, worth a combined $1.08B — down 13% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BCRX positions and 26 closed out — a net gain of 6 holders — while 84 added to existing stakes and 76 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $25.8M. The largest seller was Pictet Asset Management, cutting an estimated $24.2M.
- 235 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2023, up from 233 in Q3 2023.
- Funds reported $1.08B of BioCryst Pharmaceuticals stock for Q4 2023, down 13% quarter-over-quarter.
- 32 funds opened new BioCryst Pharmaceuticals positions in Q4 2023 and 26 closed out, a net change of +6 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $25.8M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2023 was Pictet Asset Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q4 2023.